Article type: Review Article
Article
title: Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: a literature review
Journal: Clinical
Neuropharmacology
Year: 2020
Authors: Jamir Pitton Rissardo, Ana Letícia Fornari
Caprara
E-mail: jamirrissardo@gmail.com
ABSTRACT
Background:
Carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine (ESL) acetate
belong to the dibenzazepine family. In this context, the aim of this literature
review is to evaluate the clinical epidemiological profile, pathological
mechanisms, and management of CBZ-, OXC-, and ESL-associated movement disorders
(MDs). Review Summary: Relevant reports in 6 databases were identified and
assessed by 2 reviewers without language restriction. Reports where the
individuals only developed tremor or ataxia after CBZ/OXC/ESL use were not
included. A total of 73 reports containing 191 individuals who developed MD
associated with CBZ/OXC/ESL were identified. Were found, respectively, the
following: 33 patients with myoclonus, 23 with dystonia, 14 with tics, 13 with
dyskinesia, 8 with parkinsonism, and 5 with akathisia. In the group not clearly
defined, there were 44 with myoclonus, 29 with dyskinesia, 20 with dystonia, 1
with incoordination, and 1 with akathisia. The mean age was 28.53 years. The
most frequent sex was male in 52.77% (38/72), and the drug indication was
epilepsy in 74.19% (69/93). The mean (SD) CBZ dose when the MD occurred was
692.68 (363.58) mg. The mean time until MD onset was 33.59 days, and the mean
recovery period was 8.7 days. The most common form of MD management was drug
withdrawal. Conclusions: The number of cases associated with CBZ is higher than
those with OXC + ESL. We believe that the study of CBZ contributes not only to
the improvement of this drug but also to the knowledge about the drug-induced
MD of OXC and ESL. In the literature, the description of the MD onset and
recovery has been poorly reported.
Key-Words:
Carbamazepine, oxcarbazepine, eslicarbazepine, movement disorder, drug-induced
Full
text available at:
DOI
10.1097/WNF.0000000000000387
Citation
Rissardo JP, Caprara ALF. Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: a literature review. Clin Neuropharmacol 2020;43:66-80.
